Consistent with these results, Ning et al. [29] revealed that increased expression of miR-182 was related to the resistance of NSCLC cells to cisplatin by downregulating programmed cell death 4 (PDCD4). The gene discussed is PDCD4; the disease is non-small cell lung carcinoma.